ArticleGeneral thoracic and cardiovascular surgery2026
Intraoperative landiolol hydrochloride use for prevention of postoperative atrial fibrillation with off-pump coronary artery bypass graft surgery (ILUPAF-OPCAB) study.
Article in General thoracic and cardiovascular surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Landiolol or a perioperative care bundle? Interpreting POAF prevention after OPCAB.General thoracic and cardiovascular surgery · 2026Article
Corrections and comments
- Commented on by
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePostoperative atrial fibrillation (POAF) remains a common complication after off-pump coronary artery bypass grafting (OPCAB). We evaluated the preventive effect of short-term perioperative landiolol hydrochloride administration on POAF after OPCAB.
methodsThis single-center retrospective observational study included patients who underwent elective isolated OPCAB between February 2013 and August 2018. Patients with a history of atrial fibrillation, emergency surgery, or conversion to cardiopulmonary bypass were excluded. Landiolol hydrochloride was continuously administered from the beginning of surgery until postoperative day 1. The primary endpoint was POAF occurrence. Secondary endpoints included hospital stay, perioperative complications, and healthcare insurance reimbursement points. Propensity score matching was performed to adjust baseline differences.
resultsAmong eligible patients, 74 were assigned to the control group and 159 to the landiolol group. Propensity score matching generated 68 matched pairs. POAF incidence was significantly lower in the landiolol group in both the unadjusted cohort (15.7% vs. 31.1%, p = 0.01) and propensity score matched cohort (14.7% vs. 32.4%, p = 0.02). No significant differences were observed in hospital stay or major clinical outcomes, including 30-day mortality, stroke, and prolonged intubation. However, medical insurance points were significantly lower in the matched intervention group (258,460 vs. 267,904 points, p = 0.047).
conclusionsShort-term perioperative administration of landiolol hydrochloride was associated with a lower incidence of POAF after OPCAB without an increase in perioperative complications. While further prospective randomized studies are needed, this simplified protocol may offer a safe, feasible, and potentially cost-favorable strategy for POAF prevention after cardiac surgery.
Indexed as
Identifiers
42406328What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.